Skip to main content
Pay Bill Portals

Understanding the BESPOKE CRC Study: Your Path to Confident Cancer Monitoring

Published Date

by Autumn Dangl, NP, Sr. Medical Science Liaison- Oncology

Overview of BESPOKE

The BESPOKE study was set up to gather data from hundreds of colorectal cancer patients
across multiple hospital systems, specifically stage II/III colorectal cancer patients who were monitored for recurrence after surgery or treatment using Signatera™, a tumor-informed ctDNA blood test. The goal was to understand if monitoring for molecular residual disease (MRD) using Signatera™ can help detect cancer recurrence earlier and help guide treatment decisions. Patients also completed a Hospital Anxiety and Depression Scale (HADS) questionnaire to better understand the patient's anxiety as it related to this type of testing.

Key Findings from the First BESPOKE Patient Reported Outcome (PRO) Analysis

  • 87% of patients felt reassured about their treatment after receiving their ctDNA results.
  • Almost 92% expressed interest in using ctDNA testing to monitor their cancer.
  • 96% valued the additional information from Signatera™ testing.

These findings show that Signatera™ testing can reduce anxiety about cancer recurrence and help patients feel more confident in their treatment plans.

Patient Experience and Value

  • Reduced Anxiety: 73% of patients reported that ctDNA results reduced anxiety about cancer recurrence.
  • Confidence in Treatment: 87% felt they were receiving the right treatment after receiving their results.
  • Continued Monitoring: 92% would continue using the ctDNA test to monitor cancer.
  • Additional Information: 96% valued the additional information received from ctDNA results.
Q1. ctDNA results make me less anxious about recurrence
73%
reported ctDNA results reduced anxiety about cancer recurrence
Q2. ctDNA results make me feel that I am receiving the right treatment
87%
felt they were receiving the right treatment after receiving their results
Q3. I will continue using ctDNA testing in future to monitor my cancer
92%
would continue using the ctDNA test to monitor cancer
Q4. I value the additional information ctDNA results provide me/my doctor
96%
valued the additional information received from ctDNA results

Take the Next Step

Talk with your doctor to see if Signatera™ is right for you. To learn more about Signatera testing, please visit: Signatera™ Patients For more detailed information about Signatera testing for Colorectal Cancer Survivors, please explore: Signatera™ for CRC

What is ctDNA?

  • ctDNA (circulating tumor DNA) refers to fragments of tumor DNA found in your blood after cancer surgery or treatment.
  • Signatera™ measures the presence of ctDNA in your blood over time to assess how your cancer may be responding to treatment or if it may be coming back.
  • Personalized Information: Signatera™ testing provides personalized information about your cancer, helping doctors tailor your treatment plan to optimize outcomes.

What is Signatera™

Signatera™ identifies circulating tumor DNA in the blood; these tiny fragments indicate a strong likelihood that cancer may be present. Since Signatera™ is custom-designed for each patient it can help identify relapse earlier than standard care tools. These personalized insights can help you and your doctor make informed decisions about your treatment.